Quantifying the impact of the COVID-19 pandemic on clinical trial screening rates over time in 37 countries.

McDonald, Kelsey; Seltzer, Earl; Lu, Mary; Gaisenband, Stefan Diaz; Fletcher, Cassandra; McLeroth, Patrick; Saini, Kamal S

McDonald, Kelsey; Seltzer, Earl; Lu, Mary; Gaisenband, Stefan Diaz; Fletcher, Cassandra; McLeroth, Patrick; Saini, Kamal S.

Afiliação

McDonald K; Labcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
Seltzer E; Labcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
Lu M; Labcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
Gaisenband SD; Labcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
Fletcher C; Labcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
McLeroth P; Labcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
Saini KS; Labcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA. Kamal.saini@nhs.net.

Trials ; 24(1): 254, 2023 Apr 04.

Article em En | MEDLINE | ID: mdl-37013558

Assuntos

COVID-19; Humanos; Pandemias/prevenção & controle; SARS-CoV-2; Segurança do Paciente

Palavras-chave

COVID-19; Clinical trials; Coronavirus; Enrollment; Global; Impact; Pandemic; Recruitment; SARS-CoV-2; Screening

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Clinical_trials / Diagnostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google